382 related articles for article (PubMed ID: 33719003)
41. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
Palepu J; Shrikhande SV; Bhaduri D; Shah RC; Sirohi B; Chhabra V; Dhar P; Sastry R; Sikora S
Indian J Gastroenterol; 2017 Nov; 36(6):445-451. PubMed ID: 29457213
[TBL] [Abstract][Full Text] [Related]
42. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
43. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm.
Er LM; Wu ML; Gao Y; Wang SJ; Li Y
J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27704598
[TBL] [Abstract][Full Text] [Related]
44. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.
Ito T; Igarashi H; Nakamura K; Sasano H; Okusaka T; Takano K; Komoto I; Tanaka M; Imamura M; Jensen RT; Takayanagi R; Shimatsu A
J Gastroenterol; 2015 Jan; 50(1):58-64. PubMed ID: 24499825
[TBL] [Abstract][Full Text] [Related]
45. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
46. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.
Ito T; Sasano H; Tanaka M; Osamura RY; Sasaki I; Kimura W; Takano K; Obara T; Ishibashi M; Nakao K; Doi R; Shimatsu A; Nishida T; Komoto I; Hirata Y; Nakamura K; Igarashi H; Jensen RT; Wiedenmann B; Imamura M
J Gastroenterol; 2010 Feb; 45(2):234-43. PubMed ID: 20058030
[TBL] [Abstract][Full Text] [Related]
47. Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):10-1. PubMed ID: 27168105
[No Abstract] [Full Text] [Related]
48. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.
Schimmack S; Svejda B; Lawrence B; Kidd M; Modlin IM
Langenbecks Arch Surg; 2011 Mar; 396(3):273-98. PubMed ID: 21274559
[TBL] [Abstract][Full Text] [Related]
49. Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre.
Bazarbashi S; Aseafan M; Elgazzar T; Alkhayat M; Alghabban A; Abdelgawad MI; Alshamsan B; Alshibany A; Elhassan T; Aljubran A; Alzahrani A; Alhindi H; Raef H
BMC Endocr Disord; 2023 Apr; 23(1):74. PubMed ID: 37029347
[TBL] [Abstract][Full Text] [Related]
50. Gastroenteropancreatic neuroendocrine tumours: Clinicopathological evaluation at Shifa International Hospital, Islamabad.
Mamoon N; Naveed H; Abid M; Nasir H; Ahmad IN; Hameed Z; Khan AH
J Pak Med Assoc; 2021 Feb; 71(2(A)):492-496. PubMed ID: 33819235
[TBL] [Abstract][Full Text] [Related]
51. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.
Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES
Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086
[TBL] [Abstract][Full Text] [Related]
52. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
53. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
54. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach.
Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB
Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696
[TBL] [Abstract][Full Text] [Related]
55. Gastroenteropancreatic neuroendocrine carcinoma in children and adolescents: a population-based study.
Lin W; Zhu Z; Shang Y
J Cancer Res Clin Oncol; 2024 Jan; 150(1):4. PubMed ID: 38168014
[TBL] [Abstract][Full Text] [Related]
56. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.
Altieri B; Barrea L; Modica R; Bottiglieri F; de Cicco F; Muscogiuri G; Circelli L; Savarese G; Di Somma C; Savastano S; Colao A; Faggiano A
Endocrine; 2022 Feb; 75(2):623-634. PubMed ID: 34533768
[TBL] [Abstract][Full Text] [Related]
57. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
58. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
[TBL] [Abstract][Full Text] [Related]
59. Lifestyle Factors and Development and Natural Course of Gastroenteropancreatic Neuroendocrine Tumors: A Review of the Literature.
Bogaards M; May AM; Hassan FA; Valk GD; van Leeuwaarde RS
Neuroendocrinology; 2023; 113(4):381-394. PubMed ID: 36630937
[TBL] [Abstract][Full Text] [Related]
60. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
Stiefel R; Lehmann K; Winder T; Siebenhüner AR
BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
